Kornimate/medical-research-clean huggingface dataset:
children's attention deficit disorder with hyperactivity (adhd) telemental health treatment study

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: while telemental health (tmh) programs are increasing nationally to address the inequity of access to psychiatric services, there are few reports of their efficacy, particularly with children. the current proposal will complete the second stage of our program development. in the first stage, we established the feasibility of a tmh service and its acceptability to families and pcps. in the second stage of program development we will conduct a randomized clinical trial (rct) that will determine whether it is possible to use technological advances to: 1) improve clinical outcomes for children with adhd over outcomes achieved in usual pc; and 2) adhere to an ebt protocol implemented through tmh. future studies will examine whether other types of complicated psychiatric disorders and ebts are amenable to delivery via tmh. the overall goal of this study is to determine whether an evidence-based model of care can be faithfully implemented when delivered using tmh to children with adhd living in rural areas and can improve outcomes over treatment as usual (tau) in pc. adhd is an excellent focus for assessment of tmh, as pcps encounter this disorder frequently, ebt guidelines are available, pharmacotherapy is the core treatment and is easily delivered in pc through videoconferencing, and stabilization may be readily achieved for most youth.


Eligibility criteria:
inclusion criteria: * is 5.5 - 12 years of age * resides at home with parents/relatives * has a dx of adhd (cbcl dsm-oriented elevation or previous diagnosis of adhd; c-disc diagnosis) * attends school 80% of time or more (including home-schooled children) * speaks english or spanish and parent speaks english or spanish exclusion criteria: * child has a diagnosis of: cd, ocd, psychosis, bpd, autism, mental retardation, major medical illness * resident parent has a drug use problem

Keywords: adhd telemental health tmh telepsychiatry rural mental health services for children
screening of patients with rheumatoid arthritis for interstitial lung disease

Conditions: Rheumatoid Arthritis; Interstitial Lung Disease

Summary: the quantitative and qualitative analysis of ra lung involvement in the hungarian population

interstitial lung disease (ild) accounts for a significant proportion of mortality and morbidity in rheumatoid arthritis (ra). the aim of this prospective longitudinal study is to asess the interstitial lung involvement in hungarian rheumatoid arthritis patients. laboratory markers, x-ray based imaging methods, pulmonological functional tests, qol questionnaire and sleep quality assessement questionnaire are used to estimate the interstitial lung disease. also smaller cross-sectional studies about the imaging parameters and a national register is planned to be created based on these data.

Eligibility criteria:
inclusion criteria: * diagnosis of ra exclusion criteria: * pregnancy, breastfeeding * previous diagnosis of ild, lung cancer, registered lung infection in the last 2 months

Keywords: rheumatoid arthritis interstitial lung disease
comparison of different frailty assessment tools

Conditions: Heart Failure

Summary: feasibility and comparison of the impact of different frailty assessment tools on the outcome of ventricular assist device implantation and heart transplantation in advanced heart failure patients

comparison of the feasibility and results of the following frailty assessment tools in advanced heart failure patients treated with ventricular assist device implantation or awaiting heart transplantation in eurotransplant-status "high urgency": * evaluation of the muscle mass in the preoperative ct-scan * bioelectrical impedance analysis * 6 minute walk test * grip strength measurement * questionnaires: eq5d-5l, rockwood frailty scale the assessment will be conducted prior to surgery, after surgery and at 6 month follow-up

Eligibility criteria:
inclusion criteria: * planned vad implantation/ hu-status awaiting heart transplantation * signature on informed consent exclusion criteria: * \< 18 years old * informed consent not possible/not signed * pregnancy/breastfeeding

Keywords: advanced heart failure ventricular assist device heart transplantation frailty sarcopenia bioelectrical impedance analysis muscle mass
sebum measurement in newborn to detect hyperexposure to androgens

Conditions: Polycystic Ovary Syndrome

Summary: the source of pcos is unknown. our hypothesis is that over exposure to testosterone of the foetus in utero alters the expression of genes thought to be involved in the cause of pcos.

polycystic ovary syndrome (pcos) affecting 10-15% of the female population causes excess hair, acne, irregular/absent ovulation, infertility and is associated with hypertension, diabetes, heart attacks and stroke in later life. the economic care-related burden of the syndrome is estimated at $4.36 billion/year in the usa. the root cause is unknown and although mostly familial, the offending genes are unknown. we believe that excess testosterone, to which the foetus is exposed during its life in the womb, causes development of pcos in adult life. if a mother with pcos exposes her foetus to high testosterone levels compared to one with no pcos, this would be the first step in proving the developmental hypothesis for pcos, opening the door to methods to prevent the appearance of the distressing symptoms of pcos in adult life. with no access to the foetal environment, we have used the surrogate measure of sebum on the skin of the newborn, 99% influenced by testosterone. our pilot study (homburg et al, 2017) used absorbent paper to measure sebum excretion in pcos and controls within 24 hours and 1-24 weeks after birth in mother and baby. higher sebum production in female babies of pcos mothers strongly supported our hypothesis. the present proposal utilizes a 30-second, non-invasive, quantitative measurement of sebum (sebumeter®) in the newborn from pcos mothers and controls, within 24 hours of birth. we will correlate results with other features in both female and male newborn that may suggest hyper-exposure to testosterone and with maternal testosterone levels in the blood. if confirming the findings of our pilot study in line with the developmental theory of pcos, this could be used within 24 hours of birth to predict development of pcos in adult life, induce measures to prevent the symptoms of pcos and reduce the enormous health burden on patients and economies

Eligibility criteria:
inclusion criteria: women (with and without a diagnosis of polycystic ovarian syndrome) aged 18-40 with an uncomplicated singleton pregnancy, who deliver a baby at term (37 weeks gestation or longer). women in the pcos cohort will be defined by the eshre/asrm rotterdam criteria. women with no signs of pcos who deliver a term baby will serve as the control group. exclusion criteria: patients who decline consent
recovery management intervention in china

Conditions: Methadone; HIV Infections

Summary: the purpose of the study is to develop and pilot-test a recovery management intervention (rmi) program for heroin addicts released from compulsory rehabilitation in china. the project has the following specific aims: primary aims: aim 1. to engage key stakeholders in the local communities involved in supporting the transition of heroin addicts released from compulsory rehabilitation to the community; aim 2. to identify potential barriers for participating in mmt in china; aim 3. to develop and deliver educational/training materials on hiv risks, relapse prevention, and mmt; aim 4. to adapt and develop the recovery management intervention (rmi) program for heroin addicts released from compulsory rehabilitation in china; aim 5. to conduct a pilot trial and obtain preliminary outcome data associated with rmi, relative to enhanced standard care. secondary aim: aim 6. to explore predictors of relapse and hiv/aids risk behaviors. it is hypothesized that the intervention will reduce drug use relapse and the negative consequences associated with relapse, including hiv risk behaviors


Eligibility criteria:
inclusion criteria:the study population will be drawn from all adult patients at participating compulsory rehabilitation facilities who: 1. have been incarcerated for at least one year and would have been eligible for mmt at the time of incarceration, 2. have at least 1 month remaining before release, 3. met the dsm-iv criteria for heroin dependence at the time of incarceration, 4. are willing to enroll in methadone maintenance treatment, and 5. are shanghai residents who reside in the areas of shanghai targeted by the study. exclusion criteria: individuals diagnosed with severe mental illness will not be eligible to participate.
randomized clinical trial of vitamin e and evening oil of primrose for the managment of breast pain

Conditions: Cyclical Breast Pain

Summary: this study is being done to find out what effects vitamin e or evening oil of primrose has on cyclical breast pain.

cyclical mastalgia is a common complaint of women presenting to their primary care physicians. cyclical breast pain is defined as prementstrual breast discomfort associated with hormonal fluctuations during the menstrual cycle. a clinical breast examination and sometimes additional imaging, such as sonography or mammography, is required as part of the evaluation to exclude malignancy. for most women, the symptoms are effectively managed with reassurance and conservative treatment measures such as the use of a supportive bra or over the counter pain medication such as acetaminophen or anti-inflammatories. however, a small number of women will require additional drug treatment with danazol after failing to respond to conservative measures. unfortunately, danazol is associated with significant side effects. in the mayo breast clinic, women with cyclical breast pain are managed with vitamin e and evening oil of primrose (eop) either as single agents or in combination. these over the counter supplements are readily available, acceptable due to minial side effects and appear to lead to significant reduction in breast pain. we propose a randomized placebo controlled trial to determine if any vitamin e or eop or the combination of both are effective in managing cyclical breast pain.

Eligibility criteria:
inclusion criteria: * 18 years or older * premenopausal * cyclical breast pain * breast pain survey indicating 3 or more on scale of 1-10 * if \> 40 years of age, need normal mammogram and/or ultrasound if indicated and if not done within the last year * if \< 40 years of age, a directed ultrasound in the area of pain * can be on oral contraceptives
erlotinib in treating patients with barrett esophagus

Conditions: Esophageal Cancer; Precancerous Condition

Summary: rationale: chemoprevention is the use of certain drugs to keep cancer from forming. erlotinib may keep esophageal cancer from forming in patients with barrett esophagus by blocking some of the enzymes needed for cell growth. purpose: this phase ii trial is studying how well erlotinib works in treating patients with barrett esophagus.

objectives: primary * to determine if erlotinib hydrochloride can be used as a chemopreventive agent that can cause histologic regression of barrett esophagus in patients at high risk of developing esophageal cancer associated with high-grade dysplasia. secondary * to assess whether erlotinib hydrochloride can cause molecular alterations in egfr, phospho-egfr, cyclin d1, cdc2, p16, p53, pcna, cox-2, and ploidy in barrett esophagus with high-grade dysplasia. * to establish surrogate markers of chemoprevention in barrett esophagus with high-grade dysplasia. * to validate the histologic scoring of barrett dysplasia developed by our group. * to evaluate toxicities associated with the use of erlotinib hydrochloride in patients with barrett esophagus associated with high-grade dysplasia. outline: patients receive oral erlotinib hydrochloride once daily for 3 months. patients showing no evidence of progression to cancer by esophagogastroduodenoscopy (egd) with biopsy receive an additional 3 months of treatment. all patients then undergo repeat egd, biopsy, and determination of molecular markers (i.e., egfr, phospho-egfr, cyclin d1, cdc2, p16, p53, pcna, cox-2, and ploidy). after completion of study treatment, patients are followed for 30 days.

Eligibility criteria:
disease characteristics: * diagnosis of barrett esophagus with high-grade dysplasia * refused surgery or other localized therapy for high-grade dysplasia * no invasive esophageal carcinoma patient characteristics: * anc ≥ 1,500/mm³ * platelet count ≥ 100,000/mm³ * hemoglobin ≥ 10 g/dl * bilirubin normal * ast and alt \< 3 times upper limit of normal (uln) * alkaline phosphatase \< 3 times uln * no uncontrolled medical condition * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception during and for at least 1 week after completion of study treatment * able to swallow tablets or dissolved tablets * no known hypersensitivity to erlotinib hydrochloride * no symptoms suggestive of malignancy (e.g., weight loss or vomiting) * no history of other malignancies * no uncontrolled medical or psychiatric condition that would preclude treatment under this clinical trial prior concurrent therapy: * see disease characteristics * no prior exposure to erlotinib hydrochloride * no concurrent antineoplastic or antitumor agents, including chemotherapy, radiotherapy, immunotherapy, or hormonal therapy * no concurrent investigational agents

Keywords: esophageal cancer barrett esophagus
an rct of an online training for vulnerable patients to use an online patient portal website

Conditions: Electronic Health Records; Chronic Disease; Health Literacy

Summary: online patient portals are becoming ubiquitous in the us. previous research has documented substantial usability barriers, especially among patients with limited health literacy. this pilot randomized pilot trial had the goal of determining the effectiveness of an in-person training with a scalable online video-based training program to increase portal use among patients in a safety net healthcare setting.

the intervention in this study was a patient portal training curriculum with simple instructions and 11 how-to videos for accessing features of an online patient portal. using a deeply participatory approach, this curriculum was created in consultation with a patient advisory board from the san francisco health network, a local medicaid health plan. from june until october 2016, 93 patients with 1 or more chronic diseases were randomized to receive either: 1) an in-person tutorial with a trained research assistant versus 2) a link to view the videos on their own. the primary outcome was portal log-in (yes/no) between 3 and 6 months post-training, assessed through a portal administrative dashboard within the ehr. secondary outcome included baseline and follow-up survey measures on participants' perceptions of the portal use and their care, as well as views of the web-based lessons.

Eligibility criteria:
inclusion criteria: * english-speaking as portal is only available in english * diagnosed with at least one chronic condition exclusion criteria: * cognitive impairment * visual impairment * severe mental health conditions * any circumstances that would make participation in the study difficult * no previous email use * self-reported usage of mysfhealth

Keywords: patient portal healthcare disparities safety net healthcare system
moderately hypofractionated adaptive radiotherapy for cervical cancer

Conditions: Cervical Neoplasm; Adaptive Radiotherapy; Radiotherapy; Adverse Effect

Summary: external radiation given in 25 fractions or so together with weekly chemotherapy and followed by 5 or 6 fractions of brachytherapy is the standard of care for patients with locally advanced cervical cancer. we hope to develop external moderately hypofractionated radiotherapy of cervical cancer based on adaptive radiotherapy.the objective of this study is to evaluate the efficacy and treatment-related toxicity of moderately hypofractionated adaptive radiotherapy in the treatment of cervical cancer.

this is an investigator-initiated efficacious, single-center, open-label clinical trial study. this study hypothesizes that the use of external moderately hypofractionated radiotherapy of cervical cancer based on adaptive radiotherapy. a dose of 43.35gy in 17 fractions is delivered to clinical target volume (ctv). patients receive cisplatin based concurrent chemotherapy. the primary endpoint is acute toxicity.

Eligibility criteria:
inclusion criteria: age 18 years to 70 years figo stage ib1, ib2, ib3, iia or iib cervical cancers figo stage iiic1 cervical cancers are candidates but must meet all the following criteria:largest node is less than 1.5 cm,less than 3 pathological nodes,no nodes located in the common iliac chain histology: squamous candidate for definitive chemoradiotherapy to be delivered with weekly cisplatin brachytherapy candidate functional state eastern cooperative oncology group (ecog)0-2 exclusion criteria: patients who had chemotherapeutic, surgical and/or radiotherapy treatment figo stage iiia, iiib, iiic2, iva or ivb figo stage iiic1 with node greater than 1.5 cm, common iliac node or greater than 2 pathological nodes previous pelvic or abdominal radiotherapy patient unable to undergo mr scan ecog performance status greater than 2 not a cisplatin candidate other factors that contraindicate experimental therapy

Keywords: moderately hypofractionated radiotherapy adaptive radiotherapy cervical cancer.
the effect of combined systematized behavioural modification education program (sybemep) with ddavp in patients with nocturia

Conditions: Nocturia

Summary: in patients with nocturia, combinational treatment of ddavp and sybemep might show better outcomes. systemic video instruction might prove to be beneficial by helping patients have better understanding on treatment and replacing healthcare personnel.

one of main reason of nocturia is known as nocturnal polyuria. for the treatment of nocturia caused by overactive bladder, the combined therapy of anticholinergics plus behavioural modification has been established as the first line therapy. however, nocturia mainly comes from polyuria has been treated with desmopressin pharmacotherapy and the effect of behaviour modification education has not yet evaluated. therefore, in this study, short term synergistic effect of combinational treatment of desmopressin and sybemep (systemized behavioral modification education program) comparing desmopressin monotherpy will be evaluated in patients with nocturia. control group: desmopressin (minirin tablet 0.1-0.4mg/day) + simple instruction study group: desmopressin (minirin tablet 0.1-0.4mg/day) + sybemep. patients will be randomized and assigned to each group at the ratio of 1:1. at screening visit, flowmetry and residual urine measurement, complete blood count (cbc), atypical diabetes mellitus (adm), electrolytes, urinalysis micro, urine concentration, and demographic examination will be done. voiding diary will be distributed. at 2nd visit, patients will be randomized and each treatment will be initiated. ipss, iciq-nocturia, and pptb will be completed. voiding diary will be distributed. at 3rd visit (2 weeks after from 2nd visit): ipss, iciq-nocturia, and pptb will be completed. assess the treatment outcome including voiding diary analysis.

Eligibility criteria:
inclusion criteria: * a patient with nocturia, who visited department of urology as outpatient * have not been treated with desmopressin for at least 6 months before exclusion criteria: * sleep disorder, * history of medication for voiding, * diabetes insipidus, * diabetes mellitus, * cardiovascular disease, * voiding difficulties (including residual urine of more than 100ml), * small bladder capacity, * overactive bladder, * illiteracy, * psychiatric disorder and having no intention to be enrolled by written agreement

Keywords: behavior therapy nocturia polyuria
spo2 accuracy of noninvasive pulse oximeter sensor

Conditions: Healthy; Hypoxia

Summary: the purpose of this clinical study is to validate the spo2 accuracy of the stryker sustainability solutions pulse oximetry sensors during non-motion conditions over the range of 70-100% sao2 as compared to arterial blood samples assessed by co-oximetry. the end goal is to provide supporting documentation for the spo2 accuracy validation of the reprocessed sensors.

in this study, the level of oxygen within the blood will be reduced in a controlled manner by reducing the concentration of oxygen the participant breathes. the accuracy of a noninvasive pulse oximeter sensor will be assessed by comparison to the oxygen saturation measurements from a laboratory blood gas analyzer. it is required that the accuracy root mean square (arms) performance of the stryker pulse oximetry sensors will meet a specification of +/-3% or better in non-motion conditions for the range of 70 - 100% sao2 (typically, saturation is determined once with air breathing and then at one of 6 levels, e.g. 94%, 90%, 85%, 80%, 75% and 70% saturation for about 30-60 seconds at each level), thereby demonstrating an acceptable spo2 accuracy performance specification.

Eligibility criteria:
inclusion criteria: * good general health with no evidence of pre-existing medical problems * fluent in both written and spoken english * must be able to review informed consent and is willing to comply with study procedures exclusion criteria: * obesity (bmi \>30) * known history of heart disease, lung disease, kidney or liver disease * prior diagnosis of asthma, sleep apnea, or use of cpap * diabetes * clotting disorder * hemoglobinopathy or history of anemia that in the opinion of the investigators would make them unsuitable for study participation * any serious systemic illness * current smoker * any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigator would interfere with the sensors working correctly * history of fainting or vasovagal response * history of sensitivity to local anesthesia * prior diagnosis of raynaud's disease * unacceptable collateral circulation based on exam by investigators (allen's test) * pregnant, lactating, or trying to get pregnant * unable or unwilling to provide informed consent, or unable or unwilling to comply with study procedures * any other condition which in the opinion of the investigators would make them unsuitable for the study
precision medicine of diabetes program in china

Conditions: Diabetes

Summary: the prevalence of diabetes has been increasing year by year. according to the international diabetes federation (idf) statistics in 2021, the global number of people with diabetes has reached 537 million. the patient population is large and heterogeneous, and precise diagnosis and treatment of diabetes patients have been a focus of attention. the objective of this study is to clarify the current status of precision classification and diagnosis of diabetes patients through retrospective and prospective cohort studies, and to establish a model for precision classification and diagnosis of diabetes, improving the accuracy of diabetes classification and diagnosis; based on big data of precision medicine for diabetes patients and follow-up cohorts, to establish precise diagnostic, therapeutic, and predictive methods for diabetes; and through multi-omics data analysis, to explore the potential pathogenesis of diabetes, explaining the heterogeneity of patients, and guiding individualized treatment for patients.


Eligibility criteria:
inclusion criteria: * patients diagnosed with diabetes according to who 1999 criteria exclusion criteria: * with duration more than 1 year; diabetes has not been diagnosed by who standards in 1999; absence of medical history data